- News Home
5 December 2013 11:26 am ,
Vol. 342 ,
Dyslexia, a learning disability that hinders reading, hasn't been associated with deficits in vision, hearing, or...
Exotic, elusive, and dangerous, snakes have fascinated humankind for millennia. They can be hard to find, yet their...
Researchers have sequenced and analyzed the first two snake genomes, which represent two evolutionary extremes. The...
Snake venoms are remarkably complex mixtures that can stun or kill prey within minutes. But more and more researchers...
At age 30, Dutch biologist Freek Vonk has built up a respectable career as a snake scientist. But in his home country,...
Since arriving on the island of Guam in the 1940s, the brown tree snake ( Boiga irregularis ) has extirpated native...
An animal rights group known as the Nonhuman Rights Project filed lawsuits in three New York courts this week in an...
Researchers have been hot on the trail of the elusive Denisovans, a type of ancient human known only by their DNA and...
- 5 December 2013 11:26 am , Vol. 342 , #6163
- About Us
Doubts Raised About Appetite-Reducing Peptide
7 July 2004 (All day)
Two years ago, Stephen Bloom and his group at Imperial College London touched off a scramble in labs around the world with the latest discovery of how the body regulates appetite. The investigators reported in Nature that a molecule called peptide YY3-36 (PYY3-36), when injected into rodents, dampens appetite for 12 hours or more. But in an unusual joint letter published online today by Nature, more than 40 scientists announced that they cannot reproduce Bloom's central findings.
Endocrinologist Bloom and his colleagues reported that PYY3-36 is formed in the digestive tract after eating and travels to the brain, where the peptide controls short-term appetite. Subsequently, other teams tried to reproduce the findings--without success. As word spread that several labs were experiencing similar troubles, the investigators decided to collaborate. They bought rodents from the same vendor as Bloom, purchased food from the same supplier, and injected animals at exactly the same time of day with the same kind of syringes filled with PYY3-36 manufactured by the same chemical supply house. "And still we weren't able to reproduce the results," says Mattias Tschöp of the University of Cincinnati in Ohio.
Bloom remains steadfast. Other labs "are doing the experiments badly," he suggests. He thinks the problem is stress. If an animal is handled roughly and jabbed with a needle, Bloom says, it reacts to danger by not eating. The appetite loss can negate PYY3-36's appetite-suppressing effects. (Tschöp counters that in his lab animals injected with saline did not eat any less than uninjected animals.) Bloom also points out that in two earlier cases when his initial data were challenged, he turned out to be correct after years of extra work. "It kind of gets wearing," he says.
At least one scientist has corroborated Bloom's results in rodents: Andrew Young, vice president and senior research fellow at Amylin Pharmaceuticals, headquartered in San Diego, California. His firm has a financial stake; it intends to market a drug based on PYY3-36. Asked if he knows the reason for the discrepancy, Young says, "I can't explain it. Maybe it's [a difference in] the peptide." Despite the controversy, Amylin intends to test the drug in human trials.
Tschöp admits it's possible that PYY3-36 could emerge as a powerful antiobesity drug. (His group has done no studies in people.) And one pioneer in the field, Bruce Schneider, associate vice president for clinical research at the Association of American Medical Colleges in Washington, D.C., says that conflicting data should not present a regulatory problem. The main concern is that a new drug be "reasonably" safe before entering clinical trials, says Schneider, a former medical officer at the U.S. Food and Drug Administration.